Keywords: nt, fiscal, 2nd-qtr, loss, doubles, viprinex, usa
NT's fiscal 2nd-qtr loss doubles on Viprinex
Article | 25 February 2008
The USA's Neurobiological Technologies says that its revenues for the second quarter of its 2007 fiscal year were $3.7 million compared to $4.0 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
